INSIGHTS ON DRUG DEVELOPMENT
-
![Recombinant Protein Process Development And Scale-Up]( "Recombinant Protein Process Development And Scale-Up")
Recombinant Protein Process Development And Scale-UpDiscover a resin for recombinant protein purification with a standardized protocol that streamlines workflows from lab to production, which saves time and enhances efficiency across development stages.
-
![pharma-partners-GettyImages-2182052451]( "Why Emerging Drug Developers Can't Afford To Delay Analytical Development")
Why Emerging Drug Developers Can't Afford To Delay Analytical DevelopmentRushing early pharma development by neglecting quality and analytical frameworks risks regulatory failures, clinical holds, and expensive rework.
-
![pharma-spray-drying-GettyImages-1746637448]( "Spray Dried Biologics For Injectable Dosage Forms")
Spray Dried Biologics For Injectable Dosage FormsSpray drying enables scalable production of stable, high‑concentration biologics as sterile powders, improving delivery, reducing costs, and overcoming limitations of traditional freeze‑drying methods.
-
![Innovations in medicine-GettyImages-1193139686]( "Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD)")
Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD)Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.
-
Automated Testing For Compound Toxicity Effects3/17/2025
Explore how anti-cancer drugs' toxic effects on intestinal cells limit dosages as well as how 3D organoids and assay automation can enhance drug development by improving testing processes.
-
Optimizing End-To-End Contract Analytical Support For Cell And Gene Therapies7/11/2024
The development and production of CGTs presents unparalleled complexities. Learn how a partner with robust end-to-end services can help you overcome challenges at every step of the drug lifecycle.
-
Automation Of 3D Intestinal Organoids Culture3/17/2025
Gain insight into how 3D organoids promise better disease modeling and drug screening and how challenges like assay complexity, reproducibility, and scalability hinder their widespread adoption in drug discovery.
-
Temperature Dependence On Reversed-Phase Separations7/17/2025
Column temperature critically affects the reversed-phase separation of fatty acid-modified GLP-1 RAs and impurities. Learn how precise control enhances resolution and reproducibility.
-
Predicting Performance Of Lotions Through Rheological Characterization5/6/2026
Rheological testing shows how small formulation differences influence spreading, flow, and feel during use. With minimal sample volumes, these methods connect lab measurements to real‑world performance.
DRUG DEVELOPMENT SOLUTIONS
-
![Cytiva HyClone]( "Cell Culture Media For Viral Vector Production")
Support high-yield viral vector production with media designed for transfection efficiency, scalability, and reduced aggregation in HEK293 cells, ideal for AAV and LV workflows.
-
![Laboratory scientist]( "FlexUP Technology Renewal Program")
Are you using obsolete or aging instruments simply because they continue to work? Running your laboratory with outdated technology brings about challenges beyond just headaches. Older technology may limit your performance, increase your costs, and open your lab up to risk. It may be time to investigate the real cost of using obsolete technology.
With the Waters FlexUP Technology Renewal Program, always work with the latest technology for optimum productivity and security.
-
![drug-product-GettyImages-1293772880]( "Drug Metabolism And Pharmacokinetics (DMPK)")
Curia’s DMPK scientists deliver expert solutions for your drug discovery programs. Providing bioanalytical methods development, in vitro ADMET testing and in vivo PK and PD services that span all stages of drug discovery up to candidate selection.
-
![GettyImages-1214921728-lab-glassware-beaker-vial-test-tube]( "Enhance The Solubility Of Your APIs With AI")
When it comes to solid dosage formulations, the most common challenge formulators face is poor solubility. In numbers: 70% of drugs in development are poorly soluble.
-
![Scientist Using Bioreactor GettyImages-532549174]( "Capacity To Secure Your Success")
Discover the benefits of partnering with a CDMO that offers expanding capacity and capabilities and a far-reaching operational footprint to support your project.
